Revenio Group Corporation: Managers' transactions
| Revenio Group Corporation, Stock Exchange Release, November 4, 2016 at 9.15 Managers' transactions Person subject to the notification requirement | ||
| Name: | Salovaara Olli-Pekka | Legal Person |
| Position: | Chief Executive Officer | |
| Initial Notification | ||
| Issuer | ||
| Name: | Revenio Group Oyj | |
| Transaction details | ||
| Transaction date: | 31-10-2016 | |
| Nature of the transaction: | Gift, Donation or Inheritance (Received) | |
| Instrument: | Share | |
| ISIN: | FI0009010912 | |
| Volume: | 840 | |
| Unit price: | 25,50000 Euro | |
| Aggregated transactions | ||
| Volume: | 840 | |
| Volume weighted average price: | 25.50000 Euro | |
For further information, please contact: Robin Pulkkinen, CFO, +358 50 5059932
DISTRIBUTION:
Nasdaq Helsinki
The Revenio Group in brief
Revenio is a Finnish, globally operating health technology corporation whose worldwide success is based on a strongly patented intraocular pressure measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy, in which Revenio holds a 53% interest. The common denominators of Revenio's business operations include screening, follow-up and the global need to make cost savings through preventive health care. Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The focus of Revenio's screening technology is on the early detection of glaucoma, osteoporosis, skin cancer and asthma, and the monitoring of these during the treatment process.
In 2015, Revenio Group's net sales totaled MEUR 20.3, with its operating margin for continuing operations standing at 28.4%. Revenio Group Corporation is listed on Nasdaq Helsinki.